Recce Pharmaceuticals Ltd. (RCE) AI Stock Analysis

• Market Cap: AU$154.71M
• Dividend Yield: N/A
• Average Volume (3M): 154.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: N/A
• EPS Growth: 0.66%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 289,183,400
• 10 Day Avg. Volume: 112,630
• 30 Day Avg. Volume: 154,688
• PEG Ratio: 0.34
• Price to Book (P/B): -22.52
• Price to Sales (P/S): 9.15
• P/FCF Ratio: -3.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.13
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: AU$0.51 ▲(24.63% Upside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

The score is pressured primarily by poor financial performance (declining revenue, severe losses, and negative equity). Technical indicators also point to strong bearish momentum, while valuation offers limited support due to negative earnings and no dividend yield provided.

Positive Factors

Distinct Anti‑infective Platform

Recce's synthetic polymer anti‑infective platform and lead candidate RECCE 327 represent a differentiated technology in a structurally undersupplied antibiotics market. As a clinical‑stage developer, validating this platform would create a durable competitive moat through novel mechanism and targeted programs that address drug‑resistant infections and sustain long‑term pipeline value.

Improving Free Cash Flow

A 51.97% free cash flow growth indicates improving cash generation versus prior periods, which is durable for funding clinical programs and extending the corporate runway. Stronger FCF reduces near‑term reliance on external financing and dilution, supporting continued R&D and regulatory progression over the medium term.

Positive Return on Equity

A positive 7.02% ROE suggests operational ability to extract returns from equity capital deployed. While balance sheet repairs may be needed, this metric indicates underlying efficiency in converting capital into results, a durable signal that management can generate incremental value if funding and scale are managed prudently.

Negative Factors

Revenue Decline and Deep Losses

A 21.73% revenue decline coupled with severely negative EBIT and net margins signals structural top‑line and profitability weakness. Persistently wide losses erode internal funding for R&D, increase financing needs, and weaken ability to sustain multi‑phase clinical development without recurring capital raises over the medium term.

Negative Equity / High Leverage

Negative equity and a debt-to-equity of -3.53 reflect a stressed capital structure that limits financial flexibility. This structural imbalance raises refinancing risk, constrains strategic options, and can increase cost of capital, making it harder to support sustained clinical programs or scale commercialization without materially improving the balance sheet.

Weak Operating Cash Generation

Negative operating cash flow relative to net income shows the business is not converting losses into operational cash, creating reliance on financing despite positive FCF growth. Over months, weak cash generation hampers ability to fund trials organically and elevates dilution or debt needs, pressuring long‑term program continuity.

Recce Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Recce Pharmaceuticals Ltd. (RCE) is a biotechnology company focused on the development and commercialization of innovative anti-infective therapies. The company specializes in creating synthetic polymers to combat serious infections, particularly those caused by antibiotic-resistant bacteria. Recce's lead product candidate, RECCE 327, is designed to treat a range of infections, including sepsis, and is positioned to address the growing global health challenge of antibiotic resistance.

How the Company Makes Money

null

Recce Pharmaceuticals Ltd. Financial Statement Overview

Summary

Weak fundamentals driven by a 21.73% revenue decline, deeply negative profitability (net margin -285.37%, EBIT margin -271.76%), and a highly concerning balance sheet with negative equity (debt-to-equity -3.53). Cash flow shows some improvement (free cash flow growth 51.97%) but operating cash flow remains insufficient relative to losses.

Income Statement

Recce Pharmaceuticals Ltd. has experienced declining revenue growth, with a significant drop of 21.73% in the latest year. The company is facing negative margins across the board, with a net profit margin of -285.37% and an EBIT margin of -271.76%, indicating substantial losses relative to revenue. The gross profit margin is also negative, reflecting challenges in covering production costs.

Balance Sheet

The company's balance sheet shows a concerning debt-to-equity ratio of -3.53, indicating high leverage and negative equity. Despite this, the return on equity is positive at 7.02%, suggesting some efficiency in generating returns from equity, albeit with significant risk due to negative equity.

Cash Flow

The cash flow statement reveals a positive free cash flow growth rate of 51.97%, which is a positive sign. However, the operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its net losses. The free cash flow to net income ratio is slightly above 1, showing that free cash flow is in line with net income.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	562.52K	7.51M	5.03M	4.37M	3.08M	1.64M
Gross Profit	-1.56M	-2.94M	-2.19M	4.15M	2.90M	1.34M
EBITDA	-26.98M	-20.33M	-21.35M	-16.99M	-13.87M	-14.77M
Net Income	-30.25M	-21.43M	-17.66M	-13.08M	-10.99M	-13.51M
Balance Sheet
Total Assets	2.04M	12.41M	6.37M	2.56M	12.62M	21.68M
Cash, Cash Equivalents and Short-Term Investments	602.99K	10.45M	4.42M	1.56M	11.58M	20.87M
Total Debt	11.26M	10.77M	811.19K	250.57K	74.76K	126.95K
Total Liabilities	20.66M	15.47M	15.89M	5.14M	2.56M	1.18M
Stockholders Equity	-18.62M	-3.05M	-9.52M	-2.59M	10.06M	20.50M
Cash Flow
Free Cash Flow	-23.79M	-20.47M	-13.15M	-12.73M	-9.05M	-7.93M
Operating Cash Flow	-23.75M	-20.44M	-13.01M	-12.69M	-9.01M	-7.86M
Investing Cash Flow	115.85K	-443.90K	-141.90K	-38.63K	-40.34K	-76.01K
Financing Cash Flow	22.06M	26.92M	16.00M	2.71M	-240.50K	26.12M

Recce Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RCE, the sentiment is Positive. The current price of 0.41 is below the 20-day moving average (MA) of 0.49, below the 50-day MA of 0.57, and below the 200-day MA of 0.46, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 55.51 is Neutral, neither overbought nor oversold. The STOCH value of 91.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:RCE.

Recce Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALA	52 Neutral	AU$85.71M	-14.80	-40.65%	―	700.00%	26.88%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATX	44 Neutral	AU$57.72M	-3.83	-24.81%	―	―	26.64%
PTX	42 Neutral	AU$58.88M	-5.28	-62.49%	―	―	10.78%
RCE	41 Neutral	AU$154.71M	-2.84	279.21%	―	―	0.66%
IMU	41 Neutral	AU$53.55M	-0.70	-134.65%	―	―	55.94%
ATH	41 Neutral	AU$76.13M	-2.12	-30.19%	―	―	63.46%

Recce Pharmaceuticals Ltd. Corporate Events

Recce Pharmaceuticals Issues Webinar Disclaimer on Investor Information and U.S. Offer Restrictions

Recce Pharmaceuticals has released a webinar presentation primarily comprising standard disclaimers on the nature of its materials and legal limitations on reliance by prospective investors. The document emphasizes that the presentation is not financial advice, does not constitute an offer or solicitation to buy or sell securities, and that investors must conduct their own due diligence.

The company further stresses that any references to future plans, strategies or prospects are subject to significant risks and uncertainties, with no assurances that projected outcomes will be achieved. It also underscores restrictions on offering its securities in the United States, noting that its shares are not registered under U.S. securities laws and cannot be sold there without appropriate exemptions.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.42 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Schedules Investor Webinar to Highlight Key Anti-Infective Programs

Recce Pharmaceuticals will host a live online investor webinar on 19 March 2026 to update stakeholders on its advancing anti-infective programs. The session, held via Zoom and later available as a recording, aims to broaden investor understanding of the company’s pipeline and strategic direction.

The webinar will feature expert presentations on the company’s registrational Phase 3 trial for diabetic foot infections in Indonesia and its U.S. Department of War burn wound program. Management will also outline progress across the wider anti-infective portfolio and operational highlights, underscoring Recce’s efforts to position itself as a key player in next‑generation anti‑infective therapeutics.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.42 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Deepens R&D-Driven Loss as Anti-Infective Programs Advance

Recce Pharmaceuticals reported a widened half-year loss of $16.6 million to 31 December 2025, more than doubling the prior period as it increased research and development spending, with net tangible assets per share falling further into negative territory and no dividends declared. The period also marked the passing of founder and technology inventor Dr Graham Melrose, underscoring a significant leadership and legacy transition for the company.

Operationally, the company advanced its anti-infective portfolio, including statistically significant preclinical efficacy data for topical R327G in resistant burn wound infections and strong nebulised RECCE 327 results in a pneumonia model caused by carbapenem-resistant Acinetobacter baumannii. Recce also progressed patient dosing in a registrational Phase 3 trial for diabetic foot infections in Indonesia, secured a Hong Kong patent to 2041, and obtained an Advanced Overseas Finding covering up to A$85 million of qualifying R&D, alongside expected R&D tax rebate inflows to help fund ongoing operations.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.54 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Director Options Lapse Following Scheduled Expiry

Recce Pharmaceuticals reported a change in the securities held by director James Graham, following the expiry and lapse of 2,250,000 unlisted options exercisable at $1.56 on 22 February 2026. After the change, Graham retains 3,000,000 unlisted options exercisable at $0.80 expiring in November 2029, along with 6,801,076 fully paid ordinary shares held indirectly, indicating no new issuance or disposal of shares but a routine options expiry affecting his potential equity exposure.

The adjustment in Graham’s holdings reflects scheduled option expirations rather than an active trading decision or strategic shift in ownership. For stakeholders, the notice signals a modest reduction in the director’s potential future option-derived stake, while confirming stable underlying shareholdings and no immediate capital structure impact for the company.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.54 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Options Lapse, Simplifying Capital Structure

Recce Pharmaceuticals has announced the cessation of 8,415,000 listed options (RCEAN) that expired unexercised on 22 February 2026, each carrying an exercise price of A$1.56. The expiration of these options slightly simplifies the company’s capital structure by removing a block of potential dilution for existing shareholders, but does not directly affect current operations or signal any change in strategic direction.

The notification, lodged as an Appendix 3H on 24 February 2026, formally updates the company’s issued capital on the ASX register. Stakeholders now have greater clarity over the outstanding securities on issue, which may marginally improve transparency and could influence how investors assess Recce’s future capital-raising flexibility and potential share overhang.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.54 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Deepens U.S. Army Ties With New Burn Wound Gel Study

Recce Pharmaceuticals has signed a new Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to evaluate its RECCE 327 Gel in a validated burn wound infection model that mimics battlefield injuries. The study will assess the gel’s ability to reduce bacterial burden from Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa, two major pathogens in burn patients, reinforcing Recce’s growing collaboration with U.S. government agencies and highlighting the product’s potential use as a frontline hydrogel dressing for combat, clinical and post-operative wound care amid rising antimicrobial resistance.

The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.53 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Advances Phase 3 Diabetic Foot Trial and Strengthens Anti-Infective Pipeline

Recce Pharmaceuticals reported significant operational progress in its second quarter of FY2026, advancing its registrational Phase 3 clinical trial of RECCE 327 topical gel for diabetic foot infections in Indonesia, one of the world’s largest and fastest-growing diabetes markets. The study, targeting up to 310 patients with an interim analysis at 155 patients and expedited regulatory review from Indonesian authorities, is designed to meet rigorous clinical endpoints using the FDA-recognised Lipsky Scale, positioning the company for a potential major approval in a high-cost, high-need indication. In parallel, Recce announced positive preclinical efficacy data for inhaled RECCE 327 in a murine model of hospital- and ventilator-acquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii, demonstrating both therapeutic benefit and the practical advantage of effective nebulisation over existing last-resort antibiotics like meropenem. Additional milestones during the quarter included the grant of a Hong Kong patent for its anti-infective portfolio and a substantial AusIndustry advanced overseas R&D finding of up to AUD 85 million to support its synthetic anti-infective development program, collectively strengthening its intellectual property, funding position, and strategic footing in the global anti-infective market.

The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.71 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

Recce Pharmaceuticals Secures $5.3m R&D Rebate to Bolster Anti-Infective Pipeline

Recce Pharmaceuticals has received an AUD $5.34 million cash refund under Australia’s 43.5% Research & Development Tax Incentive for eligible R&D activities undertaken in the 2025 financial year, providing non-dilutive funding to support its clinical and development programs. The company has also submitted a further claim and anticipates an additional refund of about AUD $3 million, which management says will help finance its Phase 3 clinical trial in Indonesia and other domestic studies, reinforcing its financial runway and capacity to advance its synthetic anti-infective portfolio in the highly competitive anti-infectives market.

The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.56 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.